Simple test may predict chemo risks for seniors with lymphoma
NCT ID NCT01829958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to see if this assessment can identify who is at higher risk for hospitalization, dose reductions, or severe toxicity. The study also includes a small pilot test of a low-dose pre-treatment to see if it helps reduce side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Rockville Centre
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment